Abstracts tagged "Biologic agents"

Abstract Number: 2014 • 2017 ACR/ARHP Annual Meeting
Reliability of 8-Joint Ultrasonography Scores in Follow up of Biological Therapy in Patients with Rheumatoid Arthritis
Ying-Chou Chen Sr., Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Background/Purpose: The use of biological agents, or biologics, has revolutionized the treatment of rheumatoid arthritis (RA). Using power Doppler ultrasound, this study to evaluate the…
Abstract Number: 2965 • 2017 ACR/ARHP Annual Meeting
Non-Invasive Imaging Methods for Evaluating the Cardiovascular Involvement in Patients with Rheumatoid Arthritis before and after 18 Months of Treatment with Anti-TNF Drugs
Fabiola Atzeni¹, Luigi Gianturco², Laura Boccassini³, Piercarlo Sarzi-Puttini³ and Maurizio Turiel⁴, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Beato Matteo” Hospital, GSD Foundation, Vigevano, Italy, Vigevano, Italy, ³Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ⁴IRCCS, Galeazzi Orthopedic Institute, Dept. Biomedical Sciences for Health, University of Milan, Milan, Italy
Background/Purpose: The aim of this study was to evaluate left ventricular myocardial function with two- dimensional speckle tracking echocardiography (STE), in addition to conventional Doppler…
Abstract Number: 159 • 2017 ACR/ARHP Annual Meeting
The Use of “Fibromyalgia Rapid Screening Tool” for Detection of Fibromyalgia in Patients with Chronic Arthritis Treated with Full and Tapered Biological Disease-Modifying Antirheumatic Drugs
Larissa Valor¹, Diana Hernández-Flórez², Tamara del Río², Juan Gabriel Ovalles-Bonilla³, Julia Martínez-Barrio⁴, Iustina Janta⁵, Belen Serrano⁶, Claudia Saez⁵, Roberto Gonzalez⁵, Juan Carlos Nieto⁵, Carlos M Gonzalez⁵, Indalecio Monteagudo⁵ and Francisco Javier López Longo⁷, ¹Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ²Rheumatology, Gregorio Marañón University General Hospital, Madrid, Spain, ³Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁴Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ⁷Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The coexistence of fibromyalgia (FM) and chronic arthritis is a challenge for an accurate identification of signs and symptoms associated with rheumatoid arthritis (RA),…
Abstract Number: 629 • 2017 ACR/ARHP Annual Meeting
Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?
Suneil Kapur¹, Proton Rahman², Michelle Teo³, Jodie Reis⁴, Rajwinder Dhillon⁵, Pauline Boulos⁶, Raman Rai⁷, Regan Arendse⁸, Julie Vaillancourt⁹, Emmanouil Rampakakis⁹, Allen J Lehman¹⁰, Francois Nantel¹¹ and Brendan Osborne¹¹, ¹University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Private Practice, Niagara Falls, ON, Canada, ⁶Private Practice, Dundas, ON, Canada, ⁷Private Practice, Hamilton, ON, Canada, ⁸University of Saskatchewan, Saskatoon, ON, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that treating patients earlier with biologics could improve disease outcomes. The aim of this analysis was to assess the impact…
Abstract Number: 1524 • 2017 ACR/ARHP Annual Meeting
Real-World Use of Secukinumab Among Biologic-NaïVe and Biologic-Experienced Patients with Ankylosing Spondylitis in the United States
Kurt R. Oelke¹, Rahul Garg², Yunfeng Li³, Xing Liu⁴, Huanxue Zhou⁴ and Yujin Park³, ¹Rheumatic Disease Center, Glendale, WI, ²PRO Unlimited, Inc, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴KMK Consulting, Inc, Morristown, NJ
Background/Purpose: Secukinumab is a fully human anti–interleukin-17A monoclonal antibody approved for the treatment of patients with moderate to severe ankylosing spondylitis (AS). A limited number…
Abstract Number: 2029 • 2017 ACR/ARHP Annual Meeting
Improved Provider Awareness and Delivery of Zoster Vaccination in Patients with Rheumatoid Arthritis Contemplating Biologic Therapy: Need to Target Eligible Patients Prescribed for Vaccination Post-Clinic
Gina Prakash¹, Kenneth O'Rourke² and Stephen Mullis³, ¹Department of Internal medicine, Section on Rheumatology and Immunology, Wake Forest School of Medicine, Winston Salem, NC, ²Department of Internal Medicine, Section on Rheumatology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC, ³Department of Internal Medicine, Section on Rheumatology and Immunology, Wake Forest School of Medicine, Winston Salem, NC
Background/Purpose: Vaccination against herpes zoster (shingles) can reduce the frequency of infection, the severity of shingles should it occur, and the frequency of post-herpetic neuralgia.…
Abstract Number: 210 • 2017 ACR/ARHP Annual Meeting
Pharmacovigilance Surveillance of Autoimmune Diseases Induced By Biological Agents: A Review of 12013 Cases (aeBIOGEAS-SEMI Registry)
Soledad Retamozo^1,2,3, Manuel Ramos-Casals^4,5, Marta Pérez de Lis⁶, Alejandra Flores-Chavez^7,8,9, Sofia Arteaga^10,11, Celeste Galcerán-Chaves¹², Belchin Kostov¹³, Roberto Pérez-Alvarez⁶ and Pilar Brito-Zerón^2,14, ¹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ⁴Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁵Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain, ⁶Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Vigo, Spain, ⁷Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ⁸Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁹Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ¹⁰Residente de Reumatologia II año, Universidad de Antioquia, Medellin, Colombia, Medellin, Colombia, ¹¹d) Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ¹²Neuroscience Clinical Institute, Hospital Clínic, Barcelona, Spain, Barcelona, Spain, ¹³Primary Care Research Group, IDIBAPS, Centre d’Assistència Primària ABS Les Corts, CAPSE, Barcelona, Barcelona, Spain, ¹⁴Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain
Background/Purpose: The increasing use of biological agents has been linked with the paradoxical development of autoimmune processes. The scenario has dramatically change in recent years…
Abstract Number: 635 • 2017 ACR/ARHP Annual Meeting
Short-Term Efficacy and Safety of New Biological Agents Targeting the IL-6, IL-12/23 and IL-17 Pathways for Active Psoriatic Arthritis: A Network Meta-Analysis of Randomised Controlled Trials
Dongze Wu, Jiang Yue and Lai-Shan Tam, Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: According to EULAR recommendations, in patients with peripheral arthritis and an inadequate response to at least one conventional synthetic DMARD, biologic DMARDs targeting IL-12/23,…
Abstract Number: 1525 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Patterns Among Patients with Psoriatic Arthritis Initiating Subcutaneously Administered Biologics: Descriptive Analyses from a US Claims Database
Kurt R. Oelke¹, Rahul Garg², Peter Hur³, Olivier Chambenoit³, Amar Q. Majjhoo⁴, Stephani Gray⁵, Kate Higgins⁵ and Jacqueline B. Palmer³, ¹Rheumatic Disease Center, Glendale, WI, ²PRO Unlimited, Inc, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Shores Rheumatology, St. Clair Shores, MI, ⁵Truven Health Analytics, Cambridge, MA
Background/Purpose: To better understand the real-world efficacy of biologics for the treatment of psoriatic arthritis (PsA), there is a need to evaluate the persistence and…
Abstract Number: 2266 • 2017 ACR/ARHP Annual Meeting
Patient Knowledge, Attitudes, and Beliefs Regarding Biologic Therapies in Ankylosing Spondylitis (AS): Insights from a Large-Scale Analysis of Social Media Platforms
Deeba Minhas¹, Benjamin Noah², Eldin Dzubur², Christopher Almario³, Mariko Ishimori¹, Corey Arnold⁴, Amber Howard², Carine Khalil², Alma Jusufagic², Michelle Chen², Jina Park⁵, Michael Weisman¹ and Brennan Spiegel³, ¹Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ²Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Los Angeles, CA, ³Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Cedars-Sinai Medical Center Division of Digestive and Liver Diseases, Los Angeles, CA, ⁴Medical Imaging Informatics, Department of Radiology, University of California Los Angeles, Los Angeles, CA, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: While there are multiple biologic options for ankylosing spondylitis (AS), few attempts have been made to examine patients’ knowledge and understanding of these therapies…
Abstract Number: 88 • 2017 Pediatric Rheumatology Symposium
Clinical Features and Frequency of Biologic use in Patients with Juvenile Dermatomyositis-associated Calcinosis
Amir Orandi¹, Vikas Dharnidharka², Noor Al-Hammadi³ and Kevin Baszis¹, ¹Pediatric Rheumatology, Washington University in St. Louis School of Medicine, Saint Louis, MO, ²Pediatric Nephrology, Washington University in St. Louis School of Medicine, Saint Louis, MO, ³Division of Biostatistics, Washington University in St. Louis School of Medicine, St Louis, MO
Background/Purpose: Calcinosis develops in an estimated 40% of patients with Juvenile Dermatomyositis (JDM). Conflicting studies have not definitively identified actionable risk factors or demonstrated that…
Abstract Number: 628 • 2016 ACR/ARHP Annual Meeting
Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice
M. Victoria Hernández¹, Carlos Sánchez-Piedra², Juan D. Cañete¹, Fernando Sanchez-Alonso², Javier Manero³, Ana M. Ortiz Garcia⁴, Eva Pérez-Pampin⁵, Rosa Roselló⁶, Carlos Rodriguez-Lozano⁷, Raimon Sanmarti¹, Juan J. Gómez-Reino⁵ and BIOBADASER 2.0 Study Group, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁴Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁵Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, ⁶Rheumatology, H San Jorge, Huesca, Spain, ⁷Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
Background/Purpose: Currently, the most widely used biological agents for rheumatoid arthritis (RA) patients are the inhibitors of the tumor necrosis factor (TNFi), although other biological…
Abstract Number: 1682 • 2016 ACR/ARHP Annual Meeting
Tnfα Inhibitors Are Associated with Reduced Progression of Carotid Atherosclerotic Plaques By Ultrasound and an Improvement in Aortic Arch Vascular Inflammation By 18-FDG PET/CT in Psoriasis and Psoriatic Arthritis Patients – a Prospective Study from Two Cohorts
Lihi Eder¹, Aditya Joshi², Vinod Chandran³, Amit Dey⁴, Richard J. Cook⁵, Abhishek Chaturvedi⁶, Dafna D. Gladman⁷ and Nehal Mehta⁸, ¹Medicine, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴National Institutes of Health, Bethesda, MD, ⁵Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁶National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, ⁷Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁸National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Psoriasis (PSO) and psoriatic arthritis (PsA) are chronic inflammatory diseases which are associated with increased cardiovascular (CV) diseases. Observational studies have found that TNFα…
Abstract Number: 2375 • 2016 ACR/ARHP Annual Meeting
Biologic Therapy Modifies Clinical and Laboratory Features of Macrophage Activation Syndrome Associated with Systemic Juvenile Idiopathic Arthritis
Grant Schulert¹, Francesca Minoia², John F. Bohnsack³, Randy Q. Cron⁴, Soah Hashad⁵, Isabelle Koné-Paut⁶, Mikhail Kostik⁷, Daniel J Lovell⁸, Despoina Maritsi⁹, Peter A. Nigrovic¹⁰, Priyankar Pal¹¹, Angelo Ravelli², Masaki Shimizu¹², Valda Stanevicha¹³, Bas Vastert¹⁴, Fabrizio De Benedetti¹⁵ and Alexei Grom¹⁶, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto Giannina Gaslini, Genoa, Italy, ³Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁴Pediatric Rheumatology, Children's Hospital of Alabama, Birmingham, AL, ⁵Tripoli Children's Hospital, Tripoli, Libya, ⁶Hopital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁷Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ⁸PRCSG Cincinnati Children's Hospital Medical Center, Cinncinnati, OH, ⁹2nd Department of Academic Pediatrics, Athens Medical School, university of Athens, Athens, Greece, ¹⁰Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA, ¹¹Institute of Child Health, Kolkata, India, ¹²Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan, ¹³Pediatric cathedra, Riga Stradiņš University, Riga, Latvia, ¹⁴Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, ¹⁵Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening episode of hyperinflammation and a substantial cause of morbidity and mortality in pediatric rheumatology. It occurs most…
Abstract Number: 2688 • 2016 ACR/ARHP Annual Meeting
Characteristics, Treatment and Outcome of Joint Involvement with Synovitis in Primary SjöGren’s Syndrome: French Multicentric Retrospective Case-Control Study
Adrien Mirouse¹, raphaèle seror², Xavier Mariette³, Maxime Dougados⁴, Anne-Laure Fauchais⁵, Alban Deroux⁶, Nathalie Costedoat-Chalumeau⁷, Jeremie Sellam⁸, Jean-Benoit Arlet⁹, Christian Lavigne¹⁰, Dominique Fischer-Dumont¹¹, Arsène Mékinian¹² and Olivier Fain¹², ¹Service de médecine interne, Hôpital Saint-Antoine, Paris, France, ²INSERM U1184, Paris Sud University, Le Kremlin Bicetre, France, ³INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France, ⁴Paris Descartes University, Paris, France, ⁵Department of Internal Medicine, CHU de Limoges, Limoges, France, ⁶Internal Medicine, CHU Grenoble, Grenoble, France, ⁷Internal Medicine, Cochin University Hospital, Paris, France, ⁸Rheumatology, Saint-Antoine Hospital, Paris, France, ⁹Service de médecine interne, Hopital Européen Georges Pompidou, Paris, France, ¹⁰CHU Angers, department of Internal Medicine, Angers, France, ¹¹Service de rhumatologie, Hôpital Avicenne, Bobigny, France, ¹²Service de médecine interne. Hôpital Saint-Antoine., Paris, France
Background/Purpose: primary Sjogren’s syndrome (pSS) articular manifestations include often tender joints and more rarely synovitis. The main objective of this study was to describe characteristics,…

« Previous Page
1
…
7
8
9
10
11
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].